MDNA55

From Glioblastoma Treatments
Revision as of 05:53, 24 March 2024 by Lazy (talk | contribs) (Created page with "{{TreatmentInfo |drug_name=MDNA55 |FDA_approval=No |used_for=Recurrent malignant gliomas |clinical_trial_phase=Early phase trials |common_side_effects=Not specified in the provided text |OS_with=Not specified in the provided text |PFS_with=Not specified in the provided text |usefulness_rating=3 |notes=MDNA55, a fusion of IL-4 and Pseudomonas exotoxin A, targets cells with high IL-4R expression, common in tumor tissue. Preliminary data shows significant efficacy with a 56...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search
Property Information
Drug Name MDNA55
FDA Approval No
Used for Recurrent malignant gliomas
Clinical Trial Phase Early phase trials
Clinical Trial Explanation Not specified
Common Side Effects Not specified in the provided text
OS without Not specified
OS with Not specified in the provided text
PFS without Not specified
PFS with Not specified in the provided text
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level Not specified
Toxicity Explanation Not specified

Notes: MDNA55, a fusion of IL-4 and Pseudomonas exotoxin A, targets cells with high IL-4R expression, common in tumor tissue. Preliminary data shows significant efficacy with a 56% response rate and a 20% complete response rate in recurrent glioblastoma patients treated with a single infusion, highlighting potential as a highly effective treatment.


From Ben Williams Book: Not specified

Loading comments...


Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=MDNA55&oldid=101"